Abridge is a hot streak. Currently, healthcare startups are competing for AI Talent Wars, so they are preparing to shop.
Building AI-powered software to transcription and summarise patient-doctor conversations, Abridge landed a $300 million round in June, led by Andreessen Horowitz. It was the second Mega Rays in four months. The company had raked it in a $250 million round in February.
In 18 months, Abridge raised a total of $700 million, increasing its valuation from $850 million to $5.3 billion.
Dr. Shiv Rao, CEO and co-founder of Abridge, has big plans for all of its capitals, he told Business Insider.
“We have a lot of money in the bank. We want to expand from spending 80% of that deeper and connecting the conversation to clinical notes to claims, clinical decision support and care management,” he said.
Abridge has earned the remaining 20%, according to Rao. As 80% of cash is now modest to double its technology, Abridge has earned its remaining 20%.
These transactions seem increasingly important in the brutal and competitive landscape of ambient healthcare scribes. Perhaps the most gutting release is due to Epic, the e-health records giant that first partnered with Abridge in 2023 in the startup basin. Epic is currently preparing to launch its own AI scribe, Politico reported this month. Abridge declined to comment on the report. Epic did not respond to requests for comment.
The Epic launch follows Abridge's biggest direct competitor, Healthcare Startup Ambience, and will develop its own mega-round this summer. Ambience's $250 million Series C was co-led by Oak HC/FT and A16Z. This is a longtime investor in Amience, and it appears that AI is gaining Double-Dipping in its growth investment in Apridge.
Help us improve our business, tech and innovation coverage at BI by sharing a little about your role. This will help you coordinate the content that matters most to people like you.
What is your position?
(2 of 1)
What products or services do I approve purchases in my role?
(2 of 2)
Continued
By providing this information, Business Insider agrees that this data can be used to improve the site experience and use it for targeted advertising. By continuing, you agree to accept the terms and privacy policy.
Thank you for sharing your insight into your role.
Also, Abridge is working to expand beyond Scribing to tasks like using AI to handle medical expenses, making it a match against private corporations like the new mountain capital that will pour billions of dollars into healthcare AI play.
Abridge remains at the forefront as pressure builds up. Currently, they are working with over 150 large healthcare systems, Rao said. The startup is also closely affiliated with some of these healthcare systems on new products. Abridge said Tuesday it is working with Tech's Pittsburgh Health System Highmark Health to automate pre-approval requests.
And Abridge is then focusing straight on patient provider conversations as a starting point for each new tool or acquisition target, Rao said.
“The last thing we want to do is open up trench coats and become a company that sells random things that are inconsistent with our mission,” he said. “But if there is absolutely something on our roadmap, it would be wise for us to have open ears.”
Focusing on fresh talent and skills
As San Francisco-based Abridge ran a fundraiser after the fundraiser, many startups hoping to be acquired by Abridge have entered their Rao inbox.
Rao said Abridge is not “in consultation” with a particular company, but is ready to coordinate transactions to grow faster. The startup has not made any acquisitions since its inception in 2018.
“It feels like a lot of companies are asking if they can join us in any way. We need to be able to spend that kind of thing on them, such as data play, ecosystem play, partnerships,” Rao said.
Rao said gaining top talent is Apj's biggest priority, adding that startups are competing with AI giants like Open Alli and humanity in recent recruitment efforts.
AI Talent Wars raises the stakes of startups like Abridge. As big tech companies are fighting top AI researchers, including offering wage packages for millions or tens of millions of people, startups are promoting mission-centric approaches to persuade engineers to join their teams through the tech giants.
Rao believes that Abridge can effectively compete for AI talent by providing an unusual opportunity to actually build technology that improves people's health.
“It's really important to us to find ways to recruit world-class talent as quickly as possible,” he said. “If this is the legacy you want to leave, if you want to be part of a company where you can really feel better about improving patient care every day, we will resonate more than those horizontal technology companies.”
Although Abridge has around 330 employees, Rao aims to increase significantly, especially in its engineering sector, but the company says it doesn't rely solely on M&A.
Abridge builds its own large-scale model surrounded by a widening suite of software. These models constitute a “context inference engine.” This model automates a “context inference engine” that can combine surrounding writing and related contexts from a patient's existing health records to generate practical output such as medical orders and bill code proposals. Rao said Abridge is considering purchasing data as needed to continue training the model.
With a combined build-and-buy strategy, Abridge is moving further to Revenue Cycle Management, the hottest ticket item in healthcare AI. Rao said Abridge is also working on risk adjustment, the process of estimating patient healthcare costs, value-based care arrangements and key areas in care coordination.
Abridge wants to delve deeper into clinical decision support, an area that many healthcare startups are moving away from. This is because the technology often walks thin lines to avoid facing FDA regulations. Abridge first stepped into the space in October by partnering with Medical Insights Company to surface relevant clinical evidence of Abridge's generated notes. Rao said he hopes Abridge will share more information from the partnership later this year.
As Abridge aims to take over more tasks for doctors, the company is being cautious about how it will encounter “good friction” like FDA regulations, Rao said.
“As we move towards a high-scoring workflow from a patient outcome perspective, we really, really have to be responsible,” he said. “We are trying to be as transparent as possible about how our models work and how we evaluate them. We need to be transparent as we enter these new spaces.”
